Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 6, 2013, Pages 433-443

  Mavroeidi, Vasiliki ^a   Petrakis, Ioannis ^a   Stylianou, Kostas ^a   Katsarou, Theodora ^a   Giannakakis, Konstantinos ^b   Perakis, Kostas ^a   Vardaki, Eleftheria ^a   Stratigis, Spyridon ^a   Ganotakis, Emmanuel ^a   Papavasiliou, Stathis ^a   Daphnis, Eugenios ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AKT; Diabetic nephropathy; Losartan; MTOR; Podocytes; Type 1 diabetes

Indexed keywords

LOSARTAN POTASSIUM; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; GLOMERULUS; IMMUNOFLUORESCENCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

AKT; DIABETIC NEPHROPATHY; LOSARTAN; MTOR; PODOCYTES; TYPE 1 DIABETES;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; KIDNEY GLOMERULUS; LOSARTAN; MALE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TOR SERINE-THREONINE KINASES;

ANIMALIA; RATTUS;

EID: 84879481399     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413482925     Document Type: Article

References (27)

1. Carey R.M., Siragy HM. 2003. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 14:274-281.
2. Diniz G.P., Carneiro-Ramos MS, Barreto-Chaves ML. 2009. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/ GSK-3beta/mTOR signaling pathway. Basic Res Cardiol. 104:653-667.
3. Dostal D.E., Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, Baker KM. 1997. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol. 29:2893-2902.
4. Forlenza G.P., Rewers M. 2011. The epidemic of type 1 diabetes: what is it telling us? Curr Opin Endocrinol Diabetes Obes. 18:248-251.
5. Gödel M., Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G., et al. 2011. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 121:2197-2209.
6. Hafizi S., Wang X, Chester AH, Yacoub MH, Proud CG. 2004. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. Am J Physiol Heart Circ Physiol. 287:H1232-H1238.
7. Hers I., Vincent EE, Tavaré JM. 2011. Akt signalling in health and disease. Cell Signal. 23:1515-1527.
8. Hovind P., Rossing P, Tarnow L, Toft H, Parving J, Parving HH. 2001. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care. 24:1972-1977.
9. Huang J., Manning BD. 2009. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 37:217-222.
10. Inoki K., Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Rüegg MA, Hall MN, et al. 2011. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 121:2181-2196.
11. Inoki K., Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115: 577-590.
12. Kang P.M., Landau AJ, Eberhardt RT, Frishman WH. 1994. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J. 127:1388-1401.
13. Lamprecht M.R., Sabatini DM, Carpenter AE. 2007. CellProfiler: free, versatile software for automated biological image analysis. Biotechniques. 42:71-75.
14. Lieberthal W., Levine JS. 2009. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 20:2493-2502.
15. Lloberas N., Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J., Alperovich G, Rama I, Vidal A, Grinyó JM. 2006. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 17:1395-1404.
16. Microalbuminuria Captopril Study Group. 1996. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 39:587-593.
17. Mogensen C.E., Christensen CK, Vittinghus E. 1983. The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy. Diabetes. 32(Suppl 2):64-78.
18. Mori H., Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R., Guan KL, Yoshimura A. 2009. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 384:471-475.
19. Nagai K., Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, Fukatsu A., Yanagita M, Nakano T, Ishimoto Y, et al. 2005. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 68:552-561.
20. Nemoto S., Kobayashi T, Taguchi K, Matsumoto T, Kamata K. 2011. Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol. 301:H2383-H2394.
21. Patrakka J., Tryggvason K. 2007. Nephrin-a unique structural and signaling protein of the kidney filter. Trends Mol Med. 13:396-403.
22. Sarbassov D.D., Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science. 307:1098-1101.
23. Sekulić A., Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. 2000. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60:3504-3513.
24. Troyer D.A., Kreisberg JI. 1990. Isolation and study of glomerular cells. Methods Enzymol. 191:141-152.
25. Wolf G., Chen S, Ziyadeh FN. 2005. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 54:1626-1634.
26. Yang Y., Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J. 2007. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol. 27:495-502.
27. Zhu J., Sun N, Aoudjit L, Li H, Kawachi H, Lemay S, Takano T. 2008. Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. Kidney Int. 73:556-566.